159 related articles for article (PubMed ID: 22581602)
1. Development of Guillain-Barré syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate.
Motta E; Gołba A; Huć M; Kazibutowska Z
Neurol Neurochir Pol; 2012; 46(2):189-91. PubMed ID: 22581602
[TBL] [Abstract][Full Text] [Related]
2. Glatiramer acetate for multiple sclerosis.
Drug Ther Bull; 2001 Jun; 39(6):41-3. PubMed ID: 11432030
[TBL] [Abstract][Full Text] [Related]
3. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
[TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
[TBL] [Abstract][Full Text] [Related]
5. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis.
Ziemssen T; Hoffman J; Apfel R; Kern S
Health Qual Life Outcomes; 2008 Sep; 6():67. PubMed ID: 18775064
[TBL] [Abstract][Full Text] [Related]
6. Therapy with glatiramer acetate for multiple sclerosis.
Munari L; Lovati R; Boiko A
Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
[TBL] [Abstract][Full Text] [Related]
7. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.
Soós N; Shakery K; Mrowietz U
Am J Clin Dermatol; 2004; 5(5):357-9. PubMed ID: 15554737
[TBL] [Abstract][Full Text] [Related]
8. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
[TBL] [Abstract][Full Text] [Related]
9. Normocomplementemic urticarial vasculitis in a patient with multiple sclerosis on glatiramer acetate.
Marsters C; Nathoo N; Amatto L; Wong R; Mahmood MN; McCombe JA
J Neuroimmunol; 2023 Jul; 380():578110. PubMed ID: 37267695
[TBL] [Abstract][Full Text] [Related]
10. The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis.
Ireland SJ; Guzman AA; O'Brien DE; Hughes S; Greenberg B; Flores A; Graves D; Remington G; Frohman EM; Davis LS; Monson NL
JAMA Neurol; 2014 Nov; 71(11):1421-8. PubMed ID: 25264704
[TBL] [Abstract][Full Text] [Related]
11. Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France.
Lebrun-Frenay C; Moulignier A; Pierrot-Deseilligny C; Benrabah R; Moreau T; Lubetzki C; Monchecourt F;
J Neurol; 2019 Apr; 266(4):888-901. PubMed ID: 30730008
[TBL] [Abstract][Full Text] [Related]
12. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
Ramtahal J; Jacob A; Das K; Boggild M
J Neurol; 2006 Sep; 253(9):1160-4. PubMed ID: 16990994
[TBL] [Abstract][Full Text] [Related]
13. Benefit of endermology on indurations and panniculitis/lipoatrophy during relapsing-remitting multiple sclerosis long-term treatment with glatiramer acetate.
Márquez-Rebollo C; Vergara-Carrasco L; Díaz-Navarro R; Rubio-Fernández D; Francoli-Martínez P; Sánchez-De la Rosa R
Adv Ther; 2014 Aug; 31(8):904-14. PubMed ID: 25047757
[TBL] [Abstract][Full Text] [Related]
14. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
Ball NJ; Cowan BJ; Moore GR; Hashimoto SA
J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate for the treatment of multiple sclerosis.
Wolinsky JS
Expert Opin Pharmacother; 2004 Apr; 5(4):875-91. PubMed ID: 15102570
[TBL] [Abstract][Full Text] [Related]
17. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group.
Liu C; Blumhardt LD
J Neurol Sci; 2000 Dec; 181(1-2):33-7. PubMed ID: 11099709
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].
Boyko AN; Alifirova VM
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):135-139. PubMed ID: 29265099
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and tolerability of long-term using of glatimer acetate (copaxone): a 10 year-study in the Moscow Municipal Multiple Sclerosis center].
Boĭko AN; Davydovskaia MV; Demina TL; Lashch NIu; Ovcharov VV; Popova EV; Popova NF; Romashkin AV; Boĭko OV; Khachanova NV; Sharanova SN; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):86-92. PubMed ID: 22677683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
